AKT1 and cancer: Metformin also modulates the insulin/IGF-1 signaling pathway, which is frequently overactive in cancer cells, lowering insulin and IGF-1 levels and thereby reducing PI3K/AKT/mTOR pathway activation, which decreases cell growth and induces apoptosis [12].